Introduction: Urogenital cancers include neoplasms of the urinary system (kidneys, bladder, ureters) and the male reproductive system (prostate, penis and testicles). Despite their anatomical proximity, gynecological cancers (cervix, uterus, vulva and vagina) are classified separately in epidemiological studies. Analysis of oncological surgical procedures makes it possible to assess the installed capacity, access to treatment and organization of the healthcare network. Objectives: To analyze the profile of urogenital oncological surgeries performed in Belém do Pará between 2019 and 2024. Methods: This is an observational, descriptive, and retrospective study, carried out based on the analysis of secondary data extracted from the SUS Hospital Information System (SIH/SUS) and the Oncology Monitoring Panel. Hospital admissions registered between 2019 and 2024 were included. The data were organized and tabulated in electronic spreadsheets, stratified by scope (Brazil, Pará, reference hospitals) and source of registration. A simple descriptive statistical analysis was performed, with calculation of absolute and relative frequencies, and percentage variations, in addition to the analysis of annual growth trends. Because the research used exclusively public databases with free access, it did not require submission to the Research Ethics Committee, in accordance with Resolution No. 510/2016 of the National Health Council. Results: Between 2019 and 2024, the number of urogenital surgeries in Brazil increased by 19.7%, while in the state of Pará the variation was only 3.8%, indicating stability. Nationally, the most frequently surgically treated cancers were bladder and prostate cancer. In Pará, surgeries for kidney and prostate cancer predominated. The 206.3% increase in bladder cancer surgeries and 69.2% in testicular cancer surgeries stood out. The state of Pará accounted for 1.29% of the total urogenital surgeries performed in Brazil and concentrated 31.6% of the procedures in the North Region. Oncological surgical production was centralized, with 82.27% of the procedures performed in two public reference hospitals. Conclusion: Despite the continuous growth in surgeries nationwide, production in Pará remained stable during the period analyzed. Detailed analysis of the tabulated data revealed important differences in the regional care pattern, suggesting challenges related to installed capacity, access to early diagnosis and adequate registration of oncological procedures in the state.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
